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ABSTRACT
Objective: To predict groups of cardiometabolic risk factors
within a population using demographic characteristics.
Methods: Retrospective analysis of nationally representa-
tive data from the National Health and Nutrition Exami-
nation Survey (NHANES 2001–02) was used to develop
predictive equations. Survey logistic regression was used to
model the effects of sex, age, ethnicity, and smoking status
on the presence of one of six different cardiometabolic risk
factor groups, deﬁned as: 1) abdominal obesity (AO); 2)
AO plus diabetes (DM); 3) AO plus dyslipidemia; 4) AO
plus DM plus dyslipidemia; 5) metabolic syndrome deﬁned
according to the National Cholesterol Education Program
(NCEP) (Adult Treatment Panel III) criteria; and 6) meta-
bolic syndrome deﬁned according to International Diabe-
tes Federation (IDF) criteria. Estimated coefﬁcients were
used to predict the prevalence of risk factors conditional
on the demographic characteristics of a nationally repre-
sentative population sample. Model predictions were vali-
dated using an earlier (1999–2000) release of NHANES
data.
Results: For a demographic proﬁle representative of the US
population, the model estimated the prevalence of AO; AO
and DM; AO and dyslipidemia; and AO, DM, and dyslipi-
demia to be 50.2%, 4.9%, 15.6%, and 1.9%, respectively.
The prevalence of metabolic syndrome was predicted to be
36.8% according to the NCEP deﬁnition and 39.9% accord-
ing to the IDF deﬁnition. Basic demographic variables were
signiﬁcantly associated with the presence of all six groups of
cardiometabolic risk factors. Validation of the models
demonstrated reasonable prediction of cardiometabolic risk
factors in the NHANES 1999–2000 data, including subpop-
ulations of elderly and nonwhite individuals.
Conclusions: Even where actual clinical measures are
required for diagnosis, it is possible to estimate the preva-
lence of groups of cardiometabolic risk factors using funda-
mental demographic data. Such models may be useful for
health-care providers and other decision makers for planning
purposes and general resource allocation decisions.
Keywords: cardiovascular risk, metabolic syndrome,
predictions.
Introduction
To manage health care appropriately, health plans
need to be able to estimate the prevalence of health
states. This is particularly true for conditions that are
increasing in prevalence and that are burdensome to
both patients and health plans. For some conditions,
predicting prevalence is not a simple task because data
containing disease markers are not always readily
available. This is the case with different cardiometa-
bolic risk factors, some groups of which are called
“metabolic syndrome” [1] or “syndrome X” [2].
The World Health Organization (WHO) developed
the ﬁrst formal deﬁnition of metabolic syndrome,
acknowledging that there is a constellation of risk fac-
tors for both diabetes and cardiovascular disease
(CVD) that tend to co-occur [3]. Following the publi-
cation of the WHO deﬁnition, other groups, including
the National Cholesterol Education Program (NCEP)
(Adult Treatment Panel [ATP] III) and the Interna-
tional Diabetes Federation (IDF), developed alterna-
tive deﬁnitions [4,5]. Although these deﬁnitions differ,
all recognize the fact that the prevalence of abdominal
obesity (AO), insulin resistance, dyslipidemia, and
hypertension tend to cluster and are associated with an
increased risk of developing both diabetes and CVD
[2,6–10]. The groups of risk factors also are associated
with an increased risk of mortality from CVD [11–16].
In addition, there may be a synergistic effect of these
risk factors on CVD such that the total risk is greater
than the sum of the risk for any single risk factor [12].
Recent evidence from Ford et al. using the 1999–
2002 National Health and Nutrition Examination
Survey (NHANES) suggested that the age-adjusted
rate of metabolic syndrome in US adults (20 years
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of age and older) is approximately 34.5% [17,18].
Although important from a national perspective, such
national prevalence estimates may not reﬂect preva-
lence of cardiometabolic risk within the population
covered by a health plan or community. Metabolic
syndrome has been shown to have a higher prevalence
in men, Mexican Americans and the elderly [17]. Age
is also a determinant of risk for metabolic syndrome.
For example, Ford et al. reported that the prevalence
of metabolic syndrome among NHANES participants
of 20 to 29 years old was 6.7%, compared with
43.5% for the 60 to 69 years old cohort [18]. Thus, to
the extent that the population differs from the national
population, the prevalence of different cardiometa-
bolic risk factors, including the metabolic syndrome,
also may differ.
To assess the prevalence of this condition, a health
plan needs to have access to detailed clinical data,
including information on waist circumference, fasting
plasma glucose, systolic and diastolic blood pressure,
serum triglycerides, and high-density lipoprotein lev-
els. Unfortunately, such clinical detail seldom is avail-
able in administrative data sets. To address this
problem, we sought to develop a method to estimate
the prevalence of groups of cardiometabolic risk fac-
tors using more widely available data. Our approach
was to use a nationally representative set of data that
contained the necessary clinical variables to estimate
prevalence and then to use a basic set of information
that is more likely to be available to plans (age, sex,
race/ethnicity, and smoking) to predict the prevalence
of six groups of cardiometabolic risk factors: 1) AO; 2)
AO plus diabetes (DM); 3) AO plus dyslipidemia; 4)
AO, DM dyslipidemia; 5) metabolic syndrome as
deﬁned by the modiﬁed NCEP criteria; and 6) meta-
bolic syndrome as deﬁned by IDF.
Methods
Data
Data used to develop the predictive equations were
obtained from the NHANES data 2001–02 [19].
NHANES is a nationwide probability sample survey
designed to collect nationally representative informa-
tion on the health and nutritional status of the popu-
lation of the United States through interviews and
direct physical examinations, including laboratory
testing. The laboratory data ﬁles include ﬁndings from
analyses of blood, urine, and tissue swabs collected
from a subset of the NHANES participants using
mobile examination centers. NHANES 2001–02
includes data for 11,039 persons. We excluded indi-
viduals less than 18 years of age and individuals lack-
ing data on cardiometabolic risk factors, leaving a
study sample of 5275 adults for development of the
models for AO; AO and DM; AO and dyslipidemia;
and AO, DM, and dyslipidemia. A subset of 2469 of
these individuals had the laboratory information nec-
essary for identiﬁcation of all the elements of the
NCEP cluster, and 2563 individuals had adequate lab-
oratory data for determining the IDF cluster. Because
the NHANES study was a probability survey sample
and oversampled certain segments of the population,
analyses were weighted so that results reﬂected nation-
ally representative estimates. Note also that the clus-
ters were not mutually exclusive. For example, the
criteria for AO did not exclude other comorbidities, so
patients who meet the criteria for AO may also have
DM or dyslipidemia.
Statistical Analysis
The goal of the statistical analysis was to model groups
of cardiometabolic risk factors as a function of a basic
set of demographic characteristics. Survey logistic
regression was used to determine the effect of covari-
ates on the presence of each of the six groups of car-
diometabolic risk factors examined.
Logistic regression ﬁts the probability of an event to
the cumulative distribution function of the logistic dis-
tribution. The dependent variable in our models was a
binary indicator of the presence of one of the six
deﬁned groups of cardiometabolic risk factors. Cov-
ariates included age (natural log), sex (binary indicator
for male), race (binary indicator for African American
non-Hispanic), ethnicity (binary indicator for His-
panic), and smoking status (binary indicator for
current smoker based on self-reporting of smoking fre-
quency). Because the NHANES is a complex survey
sample, a logistic regression model that accounts for
the underlying sampling units and survey design was
necessary to avoid bias and incorrect standard errors
that would otherwise result from the stratiﬁcation and
cluster sampling [20,21].
Model Description
Six separate logistic regression models were ﬁt: one for
each of the six groups of cardiometabolic risk factors.
Table 1 presents the detailed deﬁnitions of groups
studied. The estimated coefﬁcients from the ﬁtted
logistic regression were used to create equations with
which to estimate the prevalence of cardiometabolic
risk factors. A population was speciﬁed by supplying a
proﬁle of characteristics: mean age, sex (% male), race
(% African American non-Hispanic), ethnicity (% His-
panic) and smoking (% smokers). This proﬁle is used
as a weighting scheme in subsequent computations.
The resulting model computed the predicted preva-
lence of the cluster of cardiometabolic risk for each
population segment implied by the user-supplied pro-
ﬁle. For example, for a population with the following
characteristics: average age of 44 years, 48% male
(52% female), 13% Hispanic, 11% African American
(76% non-Hispanic white), and 25% current smokers
(75% nonsmokers), the model estimates the preva-
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lence for 44-year-old white female smokers, 44-year-
old African American female smokers, 44-year-old
Hispanic female smokers, etc. Risk for all segments of
the population at the average age is computed using
the following equation:
(1)
where i indexes population segments,  is a coefﬁcient
estimated from the logistic regression and pi is the pre-
dicted prevalence of the cardiometabolic risk cluster in
the population characterized by population proﬁle
xi1, . . . , xik. Once this is done for all permutations of
binary covariates, overall prevalences are estimated as
a weighted average of segment risk.
The weights are determined as the product of three
user supplied inputs: sex, race/ethnicity, and smoking.
For example, assuming as above that the population of
interest has an average age of 44 years, is 48% male,
76% white, and 25% smokers, the weight for the male
white smoker is 48% × 76% × 25% = 0.0912. The
estimated population prevalence is
(2)
where i indexes population segments, p is the popula-
tion prevalence, wi is the weight for segment i, and pi is
the predicted prevalence for population segment i as
deﬁned in Equation 2. 
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Interval Estimation
In addition to the prevalence estimate, the model also
computes a 95% conﬁdence interval for the prevalence
estimates. This was done through simulation. The
regression coefﬁcients were assumed to be jointly nor-
mally distributed with a mean vector equal to the
parameter estimates and a covariance matrix equal to
the estimated covariance matrix of the parameters. A
set of 3000 draws were taken from this normal distri-
bution and the 0.025 and 0.975 percentiles of these
draws were estimates of the lower and upper 95% con-
ﬁdence limits for the predicted prevalence. Conﬁdence
intervals around the actual prevalence estimates were
estimated directly via the standard error.
Results
Characteristics of the individuals in the NHANES
2001–02 data have been described elsewhere [22].
Characteristics of the adult subsample that was used in
the analysis are summarized in Table 2. The average
age of individuals over 18 was 45.5 and 48.0% were
males. Most individuals were white (53.4%), with
20.2% Hispanic and 26.5% African American/non-
Hispanic. Twenty percent (20.3%) were current
smokers. Table 2 also shows the national averages
implied by appropriate weighting of the data.
The odds ratios from the logistic regressions for
each of the six models are summarized in Table 3. Age
was the single most important predictor of cardiomet-
abolic risk, with older age associated with increased
risk of all six groups of cardiometabolic risk factors.
Table 1 Criteria for deﬁning groups of cardiometabolic risk factors
NCEP-ATP III 
(modiﬁed FPG) IDF AO AO and diabetes
AO and 
dyslipidemia
AO, diabetes, 
dyslipidemia
Deﬁnition 3 or more of the 
following risk factors
High WC plus 2 of
the other 4 risk 
factors
High WC High WC and 
diabetes
High WC and high 
TG or low HDL
High WC, 
diabetes, and high 
TG or low HDL
WC Men > 102 cm Men ≥ 94 cm Men > 102 cm Men > 102 cm Men > 102 cm Men > 102 cm
Women > 88 cm Women ≥ 80 cm Women > 88 cm Women > 88 cm Women > 88 cm Women > 88 cm
TG ≥150 mg/dL >150 mg/dL ≥150 mg/dL ≥150 mg/dL ≥150 mg/dL
HDL Men < 40 mg/dL Men < 40 mg/dL — Men < 40 mg/dL Men < 40 mg/dL
Women < 50 mg/dL Women < 50 mg/dL Women < 50 mg/dL Women < 50 mg/dL
BP SBP ≥ 130 or SBP ≥ 130 or — — —
DBP ≥ 85 mm HG 
or treatment of 
previously 
diagnosed 
hypertension
DBP ≥ 85 mm HG 
or treatment of 
previously 
diagnosed 
hypertension
FPG ≥100 mg/dL or 
previously 
diagnosed type 2 
diabetes or use of 
antidiabetic 
medication
≥100 mg/dL or 
previously 
diagnosed type 2 
diabetes or use of 
antidiabetic 
medication
≥126 mg/dL or 
told by doctor they 
have diabetes or 
use of antidiabetic 
medication
— ≥126 mg/dL or 
told by doctor they 
have diabetes or 
use of antidiabetic 
medication
AO, abdominal obesity; BP, blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoprotein; IDF, International Diabetes Federation;
NCEP-ATP III, National Cholesterol Education Program Adult Treatment Panel III; SBP, systolic blood pressure; TG, triglycerides; WC, waist circumference.
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Male sex was signiﬁcantly associated with increased
risk for three of the six measures: IDF, AO plus dys-
lipidemia, and AO plus both and signiﬁcantly protec-
tive for AO. Hispanic ethnicity was associated with
increased risk of two risk groups: NCEP-ATP III and
AO plus DM. African American race was positively
associated with AO and AO plus DM, and negatively
associated with IDF and AO plus dyslipidemia.
Relative to nonsmokers, smokers did not have a sig-
niﬁcantly increased risk of any of the six groups of car-
diometabolic risk factors. Full details on the estimated
coefﬁcients and their associated variance–covariance
matrices are presented in Appendix A.
The estimated prevalence of each of the six groups
of cardiometabolic risk factors is presented in Table 4.
Cardiometabolic risk deﬁned by AO had the highest
prevalence (50.2%), followed by the IDF deﬁnition of
metabolic syndrome (39.9%). The lowest prevalence
was observed for the cluster of AO plus dyslipidemia
plus diabetes.
Model Validation
To validate the model out of sample, the demographic
characteristics of an earlier cohort of NHANES
(1999–2000) were entered into each model to predict
the prevalence of each respective cardiometabolic risk
cluster. This predicted prevalence was then compared
with the actual US population prevalence. As seen in
Figure 1, predictions were close to actual prevalence in
the NHANES 1999–2000 data, with signiﬁcant over-
lap in conﬁdence intervals between the predicted prev-
alence range and the actual prevalence.
Prediction
To demonstrate how the model may be used to predict
the prevalence of groups of cardiometabolic risk fac-
tors, we estimated prevalence in two important sub-
Table 2 Summary of characteristics of individuals used in anal-
yses, NHANES 2001–02 (N = 5275)
Variable
Unweighted
mean
Weighted
mean
Age (years) 45.5 44.2
Male (%) 48.0 48.1
Female (%) 52.0 51.9
Hispanic (%) 26.5 13.2
African American/non-Hispanic (%) 20.2 10.9
White (%) 53.4 75.9
Current smoker (%) 20.3 24.0
Nonsmoker (%) 79.7 76.0
Unweighted means reﬂect averages in the sample; weighted means reﬂect national
averages.
NHANES, National Health and Nutrition Examination Survey.
Table 3 Odds ratios from survey weighted logistic regressions
Variable
NCEP-ATP III
(modiﬁed 
FPG) IDF AO
AO and 
diabetes
AO and 
dyslipidemia
AO, diabetes,
dyslipidemia
Age (log) 7.7 6.1 3.6 18.8 2.6 22.8
(<0.0001) (<0.0001) (<0.0001) (<0.0001) (<0.0001) (<0.0001)
Male 1.1 1.3 0.4 0.9 2.2 2.1
(0.3440) (0.0400) (<0.0001) (0.5090) (<0.0001) (<0.0001)
Female Reference
Hispanic 1.7 1.2 1.1 1.4 0.9 1.1
(0.0300) (0.1970) (0.4330) (0.0480) (0.3500) (0.5370)
African American 0.9 0.9 1.2 2.2 0.5 0.9
(0.5760) (0.0220) (0.0160) (<0.0001) (<0.0001) (0.8110)
White Reference
Current smoker 1.2 1.1 0.9 1.1 1.1 1.4
(0.2000) (0.6830) (0.2900) (0.6310) (0.3280) (0.2830)
Nonsmoker Reference
P-values are in parentheses.
AO, abdominal obesity; FPG, fasting plasma glucose; IDF, International Diabetes Federation; NCEP-ATP III, National Cholesterol Education Program Adult Treatment Panel III.
Table 4 Summary of prevalence of cardiometabolic risk factors in NHANES
Cardiometabolic risk cluster
Predicted
prevalence (%)
95% conﬁdence interval 
Lower (%) Upper (%)
NCEP-ATP III 36.8 34.8 38.3
IDF 39.9 38.2 41.3
Abdominal obesity 50.2 48.7 51.9
Abdominal obesity + diabetes 4.9 4.2 6.1
Abdominal obesity + dyslipidemia 15.6 14.5 16.5
Abdominal obesity + dyslipidemia + diabetes 1.9 1.5 2.5
IDF, International Diabetes Federation; NCEP-ATP III, National Cholesterol Education Program Adult Treatment Panel III; NHANES, National Health and Nutrition Examination
Survey.
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samples from the 1999–2000 NHANES cohort: the
elderly (age ≥ 65 years) and nonwhites. Demographic
characteristics that were used as inputs for these esti-
mates are presented in Table 5. Results for the elderly
are summarized in Figure 2 and suggest that preva-
lence is generally greater for the elderly and that the
models provide reasonable estimates of prevalence.
Prediction of cardiometabolic risk factors among non-
whites is presented in Figure 3, and also suggests that
the models provide reasonable estimates. Actual prev-
alence for each group fell within the 95% conﬁdence
interval of the predicted value.
Discussion
Determining the prevalence of groups of cardiometa-
bolic risk factors, such as metabolic syndrome, in a
speciﬁc population is not always possible because of
the need for clinical measures. Because such clinical
information is seldom available in health insurer,
managed care and health system electronic data sys-
tems, and community-level information, these groups
have had limited ability to determine the risk burden
of their populations. This study demonstrated that it
is possible to estimate the prevalence of common and
important cardiometabolic risk factors using basic,
widely available demographic data. Furthermore, val-
idation suggested that predicted prevalence from the
model was reﬂective of actual prevalence in a similar
set of data, although additional validation is needed
in other data sets. Nevertheless, predictive models
such as those presented here may be useful for health-
care providers and decision makers in estimating the
Figure 1 Summary of validation of prediction model on National Health
and Nutrition Examination Survey 1999–2000 data. Filled circles are the
actual prevalence of the groups, open circles represent prevalence pre-
dicted by the model. AO, abdominal obesity; IDF, International Diabetes
Federation; NCEP-ATP III, National Cholesterol Education Program Adult
Treatment Panel III.
Prevalence
0.60.40.20.0-0.2
NCEP ATP III
IDF
AO
AO + Diabetes
AO + Dyslipidemia
AO + Diabetes + Dyslipidemia
Predicted
Actual
Figure 2 Prediction of the prevalence of groups of cardiometabolic risk
factors among the elderly. Filled circles are the actual prevalence of the
groups, open circles represent prevalence predicted by the model. AO,
abdominal obesity; IDF, International Diabetes Federation; NCEP-ATP III,
National Cholesterol Education Program Adult Treatment Panel III.
Prevalence
NCEP ATP III
IDF
AO
AO + Diabetes
AO + Dyslipidemia
AO + Diabetes + Dyslipidemia
Predicted
Actual
0.60.40.20.0-0.2
Figure 3 Prediction of the prevalence of cardiometabolic risk factors
among nonwhites. Filled circles are the actual prevalence of the groups,
open circles represent prevalence predicted by the model.  AO, abdominal
obesity; IDF, International Diabetes Federation; NCEP-ATP III, National
Cholesterol Education Program Adult Treatment Panel III.
Prevalence
NCEP ATP III
IDF
AO
AO + Diabetes
AO + Dyslipidemia
AO + Diabetes + Dyslipidemia
Predicted
Actual
0.60.40.20.0-0.2
Table 5 Characteristics of subsamples of NHANES 1999–
2000 data used in predicting groups of cardiometabolic risk
factors
Variable Elderly Nonwhite
Age (years) 73.5 40.3
Male (%) 43.8 45.8
Female (%) 56.2 54.2
Hispanic (%) 8.4 57.5
African American/non-Hispanic (%) 7.6 42.5
White (%) 84.0 0.0
Current smoker (%) 10.8 22.2
Nonsmoker (%) 89.2 77.8
NHANES, National Health and Nutrition Examination Survey.
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prevalence of these conditions when clinical measures
are unavailable. They may also be useful to health
plans and communities for prioritizing and allocating
resources for interventions that reduce the risk of
diabetes and cardiovascular events in affected
populations.
The prevalence estimates that we obtained for the
NCEP and IDF deﬁnitions of metabolic syndrome are
very similar to those recently reported in the literature.
Ford, also using NHANES data, reported an age-
unadjusted prevalence of metabolic syndrome of
34.5% using the NCEP deﬁnition and 39.0% using the
IDF deﬁnition [17,18]. These are very similar to the
prevalence we report of 36.8% for NCEP and 39.9%
for IDF. There are several possible reasons for the
slight differences noted. First, although Ford combined
data from 1999–2000 and 2001–02, our models were
developed only on the more recent 2001–02 data. Evi-
dence suggests that the prevalence of obesity as well as
metabolic syndrome is increasing, which may account
in part for the higher NCEP prevalence in our study. In
addition, Ford included patients over 20 years of age,
whereas the current study included all adults age 18 or
older. Another difference is the clinical deﬁnition of
fasting plasma glucose (FPG). Ford [18] used impaired
fasting glucose deﬁned as ≥110. Nevertheless, Ford
[17] and this study applied a more recent clinically rec-
ognized deﬁnition of FPG 100–125.
This study focused on six groups of cardiometa-
bolic risk factors. In fact, given the possible permuta-
tions of risk factors, there are many more that might
have been examined. We chose to focus on groups that
include AO because in the US general population this
risk factor has increased dramatically, driving up the
prevalence of metabolic syndrome [23]. We also chose
to focus on the two deﬁnitions of metabolic syndrome
that receive the most attention, although we recognize
that others have deﬁned this clustering of cardiometa-
bolic risk factors somewhat differently [3,24]. The val-
idation may have been limited since it was performed
on an NHANES data set. A less conservative valida-
tion would apply the model in data sets that are less
similar to the data used to develop the model. Finally,
we recognize that there is controversy surrounding the
concept of metabolic syndrome itself [25]. Some inves-
tigators have questioned whether any groups of cardi-
ometabolic risk factors warrant classiﬁcation as a
syndrome, given the differences in deﬁnitions and the
lack of evidence from which to set threshold for risk
factors. In addition, some deﬁnitions of metabolic
syndrome have been criticized for including diabetes
when, it is argued, the development of diabetes should
be predicted by the syndrome.
Regardless of the controversy surrounding meta-
bolic syndrome, risk factors for CVD and diabetes do
cluster and their prevalence is increasing [26]. Individ-
uals who have these conditions are undoubtedly high
utilizers of health-care resources and thus are costly to
plans. As well, medical providers may be well advised
to treat the constellation of risk factors associated with
this clustering rather than focusing on one risk factor
at a time.
As health plans increasingly seek efﬁcient ways to
manage costly patients, means of estimating the size of
the problem in the populations for which they have
responsibility is an important initial step in the proc-
ess. Thus, the models presented here may be a useful
starting point in that process.
Source of ﬁnancial support: The project was funded by
sanoﬁ-aventis. 
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Appendix A: All Estimated Coefﬁcients and Associated Variance–Covariance Matrices
Variable Coefﬁcient
Standard
error
Variance–covariance matrix 
Log age Male Hispanic African American Smoker Intercept
NCEP-ATP III
Log age 2.036 0.190 0.036 — — — — —
Male 0.110 0.112 0.000 0.013 — — — —
Hispanic 0.504 0.211 −0.016 −0.005 0.044 — — —
African American/non-Hispanic −0.053 0.093 −0.003 0.006 −0.002 0.009 — —
Current smoker 0.165 0.123 0.002 0.003 0.003 0.002 0.015 —
Intercept −8.424 0.735 −0.138 −0.008 0.057 0.005 −0.017 0.541
IDF
Log age 1.807 0.245 0.060 — — — — —
Male 0.239 0.113 0.017 0.013 — — — —
Hispanic 0.185 0.128 −0.011 −0.002 0.016 — — —
African American/non-Hispanic −0.155 0.068 0.002 0.003 0.003 0.005 — —
Current smoker 0.054 0.120 0.003 0.004 0.005 0.004 0.014 —
Intercept −7.402 0.957 −0.234 −0.069 0.040 −0.010 −0.016 0.916
Abdominal obesity (AO)
Log age 1.281 0.116 0.014 — — — — —
Male −0.817 0.073 −0.001 0.005 — — — —
Hispanic 0.069 0.086 0.000 0.000 0.007 — — —
African American/non-Hispanic 0.173 0.064 −0.002 0.001 0.001 0.004 — —
Current smoker −0.080 0.073 0.002 0.001 0.002 0.002 0.005 —
Intercept −4.468 0.442 −0.051 −0.001 −0.001 0.005 −0.010 0.195
AO + diabetes
Log age 2.932 0.213 0.045 — — — — —
Male −0.082 0.121 0.014 0.015 — — — —
Hispanic 0.315 0.146 0.017 0.003 0.021 — — —
African American/non-Hispanic 0.799 0.159 0.007 0.001 0.009 0.025 — —
Current smoker 0.074 0.150 0.009 0.005 0.010 −0.004 0.022 —
Intercept −14.226 0.950 −0.202 −0.064 −0.078 −0.038 −0.045 0.902
AO, abdominal obesity; IDF, International Diabetes Federation; NCEP-ATP III, National Cholesterol Education Program Adult Treatment Panel III.
Predicting Clusters of Cardiometabolic Risk Factors S11
AO + dyslipidemia
Log age 0.970 0.105 0.011 — — — — —
Male 0.775 0.096 0.003 0.009 — — — —
Hispanic −0.134 0.139 0.004 −0.004 0.019 — — —
African American/non-Hispanic −0.780 0.163 −0.003 0.003 −0.006 0.026 — —
Current smoker 0.120 0.119 0.000 −0.002 0.000 −0.007 0.014 —
Intercept −5.739 0.425 −0.044 −0.016 −0.016 0.013 −0.003 0.180
AO + diabetes + dyslipidemia
Log age 3.127 0.166 0.028 — — — — —
Male 0.745 0.161 0.007 0.026 — — —
Hispanic 0.131 0.207 0.016 −0.008 0.043 — — —
African American/non-Hispanic −0.052 0.215 −0.004 0.001 0.001 0.046 — —
Current smoker 0.349 0.313 −0.007 −0.018 −0.023 0.023 0.098 —
Intercept −16.328 0.755 −0.124 −0.038 −0.067 0.004 0.011 0.570
Variable Coefﬁcient
Standard
error
Variance–covariance matrix 
Log age Male Hispanic African American Smoker Intercept
AO, abdominal obesity; IDF, International Diabetes Federation; NCEP-ATP III, National Cholesterol Education Program Adult Treatment Panel III.
Appendix A: continued
